La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Kymera Therapeutics Croissance future
Future contrôle des critères 2/6
Kymera Therapeutics's earnings are forecast to decline at 5.1% per annum while its annual revenue is expected to grow at 22.7% per year. EPS is expected to decline by 0.5% per annum. Return on equity is forecast to be -134.4% in 3 years.
Informations clés
-5.0%
Taux de croissance des bénéfices
-0.3%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 30.4% |
| Taux de croissance des recettes | 22.7% |
| Rendement futur des capitaux propres | -62.9% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 20 Aug 2024 |
Mises à jour récentes de la croissance future
Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results
Aug 11
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43
Feb 25Recent updates
Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results
Aug 11Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up
Jul 14Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being
Jun 12We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth
May 03Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith
Mar 21Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43
Feb 25Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking
Feb 17Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up
Dec 29We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully
Nov 06Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts
Aug 31Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Aug 04Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up
May 21We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely
Apr 16Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth
Dec 28Kymera KT-333 gets FDA orphan drug status for blood cancer subtype
Sep 15Kymera initiated at buy at Jefferies on promise in oncology, autoimmune spaces
Aug 15Kymera Therapeutics GAAP EPS of -$0.78 misses by $0.08, revenue of $11.51M misses by $3.46M
Aug 09Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 76 | -283 | -180 | -186 | 15 |
| 12/31/2025 | 72 | -264 | -181 | -172 | 18 |
| 12/31/2024 | 60 | -213 | -187 | -160 | 17 |
| 6/30/2024 | 89 | -158 | -138 | -106 | N/A |
| 3/31/2024 | 79 | -155 | -136 | -98 | N/A |
| 12/31/2023 | 79 | -147 | -137 | -103 | N/A |
| 9/30/2023 | 47 | -167 | -174 | -150 | N/A |
| 6/30/2023 | 52 | -158 | -169 | -153 | N/A |
| 3/31/2023 | 47 | -159 | -163 | -157 | N/A |
| 12/31/2022 | 47 | -155 | -156 | -153 | N/A |
| 9/30/2022 | 46 | -154 | -155 | -152 | N/A |
| 6/30/2022 | 57 | -139 | -157 | -155 | N/A |
| 3/31/2022 | 64 | -124 | -148 | -146 | N/A |
| 12/31/2021 | 73 | -100 | -131 | -129 | N/A |
| 9/30/2021 | 70 | -79 | -113 | -111 | N/A |
| 6/30/2021 | 65 | -58 | 54 | 58 | N/A |
| 3/31/2021 | 49 | -48 | 69 | 77 | N/A |
| 12/31/2020 | 34 | -55 | 79 | 88 | N/A |
| 9/30/2020 | 23 | -53 | 90 | 97 | N/A |
| 6/30/2020 | 9 | -57 | -52 | -47 | N/A |
| 3/31/2020 | 6 | -52 | -17 | -15 | N/A |
| 12/31/2019 | 3 | -41 | 17 | 18 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: KYMR is forecast to remain unprofitable over the next 3 years.
Bénéfices vs marché: KYMR is forecast to remain unprofitable over the next 3 years.
Croissance élevée des bénéfices: KYMR is forecast to remain unprofitable over the next 3 years.
Chiffre d'affaires vs marché: KYMR's revenue (22.7% per year) is forecast to grow faster than the US market (8.8% per year).
Croissance élevée des revenus: KYMR's revenue (22.7% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: KYMR is forecast to be unprofitable in 3 years.